The results concerning the role of cPLA2 in EGF-induced PAF production, along with the convergence of signaling molecules on cPLA2, suggest that cPLA2 may be a potential therapeutic target in ovarian cancer. This evidence concerns the gene PLA2G4A and ovarian carcinoma.